Aytu Biopharma Inc (AYTU)

Nov 16, 2024

Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Nov 16, 2024

Nov 16, 2024

Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World

Nov 16, 2024

Nov 15, 2024

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Nov 15, 2024

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Nov 14, 2024

Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks

Nov 13, 2024

Nov 13, 2024

Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch

Nov 13, 2024

Nov 13, 2024

Aytu Biopharma, Inc. Announces Chief Financial Officer Changes - Marketscreener.com

Nov 13, 2024

Nov 13, 2024

Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500

Nov 13, 2024

Nov 08, 2024

Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia

Nov 08, 2024

Nov 05, 2024

Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail

Nov 05, 2024

Nov 05, 2024

Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR

Nov 05, 2024

Nov 01, 2024

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St

Nov 01, 2024

Nov 01, 2024

AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia

Nov 01, 2024

Oct 29, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Oct 29, 2024

Oct 23, 2024

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

Oct 23, 2024

Oct 22, 2024

AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com

Oct 22, 2024

Oct 14, 2024

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire

Oct 14, 2024

Oct 11, 2024

Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia

Oct 11, 2024

Oct 09, 2024

Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa

Oct 09, 2024

Oct 06, 2024

Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle

Oct 06, 2024

Oct 03, 2024

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Oct 03, 2024

Oct 01, 2024

Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada - Investing.com Canada

Oct 01, 2024

Oct 01, 2024

Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada By Investing.com - Investing.com South Africa

Oct 01, 2024

Oct 01, 2024

AYTUAYTU BioPharma, Inc. Latest Stock News & Market Updates - StockTitan

Oct 01, 2024

Oct 01, 2024

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - StockTitan

Oct 01, 2024

Sep 28, 2024

Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Sep 28, 2024

Sep 27, 2024

Earnings call: Aytu BioPharma reports turnaround with focus on ADHD By Investing.com - Investing.com South Africa

Sep 27, 2024

Sep 27, 2024

Earnings call: Aytu BioPharma reports turnaround with focus on ADHD - Investing.com

Sep 27, 2024

Sep 27, 2024

When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - Simply Wall St

Sep 27, 2024

Sep 26, 2024

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results - AccessWire

Sep 26, 2024

Sep 19, 2024

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 - AccessWire

Sep 19, 2024

Sep 19, 2024

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

Sep 19, 2024

Sep 19, 2024

Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Sep 19, 2024

Sep 19, 2024

Anterix (NASDAQ:ATEX) Sees Unusually-High Trading Volume - Defense World

Sep 19, 2024

Sep 19, 2024

Atlantica Sustainable Infrastructure (NASDAQ:AY) Now Covered by StockNews.com - Defense World

Sep 19, 2024

Sep 18, 2024

Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug - Benzinga

Sep 18, 2024

Sep 18, 2024

Altamira Therapeutics announces pricing of $12M offering - TipRanks

Sep 18, 2024

Sep 15, 2024

Jupiter Asset Management Ltd. Makes New Investment in Anterix Inc. (NASDAQ:ATEX) - Defense World

Sep 15, 2024

Sep 08, 2024

Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Yahoo Finance

Sep 08, 2024

Sep 06, 2024

Comparing Sanofi (NASDAQ:SNY) & Aytu BioPharma (NASDAQ:AYTU) - Defense World

Sep 06, 2024

Aug 20, 2024

Alaska Air clears hurdle in proposed merger with Hawaiian Airlines - Head Topics

Aug 20, 2024

Aug 19, 2024

Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update - Defense World

Aug 19, 2024

Aug 15, 2024

Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.77 - Defense World

Aug 15, 2024

Aug 08, 2024

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 - AccessWire

Aug 08, 2024